Elizabeth White Email & Phone Number

The Orphan Therapeutics Accelerator is a non-profit biotech company focused on efficiently advancing promising “shelved” treatments for ultra-rare conditions through late-stage clinical development and approvals, and providing a viable commercial pathway to make them available to patients in need. Our model utilizes tax and other incentives to dramatically.

• Biotechnology consulting practice offering the following services:
• New Company Formation, Financing, and Corporate Strategy
• Business Development and Licensing / Acquisition Strategy
• Strategic Business Planning and Budgeting
• Operations, Program Management, and Drug Development Strategy
• Portfolio Valuation and Decision Analysis

Led business development, strategic planning, and operations for Renovacor, Inc., a preclinical public gene therapy company focused on developing targeted therapies for rare genetic cardiovascular diseases. o Led business development efforts resulting in Rocket Pharma’s acquisition of Renovacor. o Managed corporate infrastructure development, program.

King Of Prussia, Pennsylvania, US

Led strategic business planning for this pre-clinical start-up gene therapy company focused on neural trans-differentiation for neurodegenerative conditions including stroke, Huntington’s disease, ALS and Alzheimer’s disease. o Drove fundraising efforts that ultimately resulted in the successful execution of $10+ million Series Pre-A financing raise. o.

Business Development and New Product Planning Strategy Consultant focused on Rare Disease, Biologics and Gene Therapy.

New York, New York, US

• Led the end-to-end new product planning strategy for Rare Disease and Gene Therapy Business Unit.
• Enabled Pfizer's decision to establish a Business Unit focused on rare diseases and led the development of the cross-functional long-term strategic and operational plan that was endorsed by senior management.
• Built Pfizer’s Rare Disease / Gene Therapy business by facilitating the completion of many successful licensing and acquisition deals, including partnerships with Spark Therapeutics and Sangamo Therapeutics, and the.
• Directed numerous commercial analyses, providing insights on unmet medical needs, competitive differentiation and positioning, market value, and market access strategies to support target product profile development.
• Launched and led a working group focused on patient and advocacy engagement, finding innovative ways to involve patients throughout development, resulting in important clinical development plan improvements.
• Strengthened Pfizer’s reputation by building and launching new rare disease and gene therapy communications strategy and tools, and by speaking at many key conferences.

New York, New York, US

• Led the development and execution of new product planning strategy for seven disease areas within the Specialty Care Business Unit including inflammation, specialty cardiovascular disease, renal disease, hospital.
• Initiated and led cross-Pfizer team to drive coordination and communication between biosimilars and innovative biologics businesses, improving decision-making and execution.
• Successfully delivered streamlined portfolio strategy for new Specialty Care Business Unit.
• Managed team of directors with responsibility for improving development plans, portfolio prioritization and in-licensing decisions by incorporating important market perspectives.

New York, New York, US

• Led development of long-term strategic business plans and optimization of development asset portfolios in the inflammation, oncology, and tissue repair therapeutic areas.
• Led a team that provided commercial analysis and insights on unmet medical needs, competitive differentiation and positioning, market value, key stakeholders, and market access challenges for 18 development programs.
• Created and led matrix team that gained management consensus on biosimilars strategy.

New York, New York, US

• Built global life cycle strategy and provided business leadership for Enbrel, the leading biotechnology brand in the world, with global sales exceeding $6B in 2008.
• Created and led cross-indication Global Brand Leadership Team which gained senior management approval of comprehensive multi-indication, long-term life cycle strategy.
• Delivered process improvements for the complex, cross-functional Enbrel Global Brand Teams resulting in improved decision-making internally and for external Amgen alliance.
• Developed Enbrel biosimilars strategies, including management of first Wyeth biosimilars in China and Colombia and worldwide rollout of corporate biosimilar policy position.

New York, New York, US

• Led the long-term strategy for new Enbrel formulations, devices and dermatology business.
• Collaborated with the manufacturing organization to lead efforts that resulted in corporate approval to develop pre-filled syringe, auto-injector (MyClic), pediatric indication and packaging, and room temperature.

New York, New York, US

• Supported international operations with financial tracking, communications, process improvements.
• Led corporate policy improvements including expansion of global patent filing strategy and consolidation of budgeting process, resulting in efficiency and new business opportunity.
• Facilitated new business unit structure development, led planning of global senior meetings.

Phd, Master Of Science (Ms), Cell/Cellular And Molecular Biology

Bachelor Of Science (Bs), Biology